Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Conditions
mCRPC (Metastatic Castration-resistant Prostate Cancer) · Genital Diseases, Male · Urogenital Diseases, Male · Prostatic Disease · Prostatic Neoplasms, Castration-Resistant · Prostate Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Centre Jean Perrin, Clermont-Ferrand, France
Institut Paoli-Calmettes, Marseille, France
Centre Antoine Lacassagne, Nice, France
Institut Gustave Roussy, Villejuif, France
Hospital Clinic Barcelona, Barcelona, Spain
Institut Catala d'Oncologia, Barcelona, Spain
Hospital General Universitario Gregorio Maranon, Madrid, Spain
Hospital 12 de Octubre, Madrid, Spain
Instituto Valenciano de Oncología, Valencia, Spain
Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospita, Cambridge, United Kingdom
University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, United Kingdom
Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Study leads
Nadene Zack, MS
Study Director
Celcuity Inc